Two-year toxicity of simultaneous integrated boost in hypofractionated prone breast cancer irradiation: comparison with sequential boost in a randomized trial

In addition to surgery and chemotherapy, radiotherapy (RT) is one of the foundations of breast cancer treatment. With a few exceptions, breast conserving surgery (BCS) is followed by RT[1]. After whole breast irradiation (WBI), an additional boost on the tumour bed has demonstrated to reduce the risk of relapse in the ipsilateral breast. A sequential boost (SEB) typically consists of 4 to 8 extra fractions [2,3] and thus increases the duration of treatment by 1 to 2 weeks. A simultaneous integrated boost (SIB) reduces the burden of breast cancer treatment for the patient by shortening the duration of RT [4].

Source: Radiotherapy and Oncology - February 19, 2021 Category: Radiology Authors: Hans Van Hulle, Eline Desaunois, Vincent Vakaet, Leen Paelinck, Max Schoepen, Giselle Post, Annick Van Greveling, Bruno Speleers, Marc Mareel, Wilfried De Neve, Chris Monten, Pieter Deseyne, Liv Veldeman Tags: Original Article Source Type: research